ARTICLE | Company News
Abzena, Alpha Cancer deal
June 16, 2014 7:00 AM UTC
Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will use its ThioBridge linker technology to attach an undisclosed cytotoxic drug to Alpha Cancer's recombinant human alpha fetoprotein (AFP) that targets AFP receptors. Alpha Cancer has exclusive, worldwide rights to recombinant human AFP from Merrimack Pharmaceuticals Inc. (NASDAQ:MACK, Cambridge, Mass.). PolyTherics and Alpha Cancer could not be reached for details. ...